Broida Samuel E, Sullivan Mikaela H, Cleary Emmett J, Rose Peter S, Wenger Doris E, Houdek Matthew T
Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
J Surg Oncol. 2025 Jul;132(1):205-209. doi: 10.1002/jso.28139. Epub 2025 May 14.
Skip lesions in bone sarcoma are a poorly described entity. Reports on skip lesions in osteosarcoma and Ewing sarcoma suggest that whole bone MRI should be obtained to evaluate for additional tumor foci given the association with worse outcomes. However, there is limited evidence to support whole bone imaging in chondrosarcoma.
Between 1995 and 2022, 129 patients with long bone chondrosarcoma were evaluated at our institution. Lesions were located most commonly in the femur in 64 patients and the humerus in 54 patients. All imaging studies and pathology reports were reviewed to determine the presence of skip lesions, defined as an area of histology-confirmed chondrosarcoma that was separated from the primary lesion by normal bone on pathology.
Whole bone imaging was obtained during initial staging in 107 patients with two-thirds of patients receiving MRI, CT, or bone scan. Five patients (3.9%) were found to have skip lesions in the same bone as the primary tumor. There were no transarticular skip lesions. Skip lesions were detected in three patients with low grade chondrosarcoma (4.6%) and two patients with high grade chondrosarcoma (3.2%). All lesions were within 2 cm of the primary tumor. All were visible on MRI and CT of the primary site and one was visible on plain radiographs. The presence of skip lesions did not alter the type of surgical treatment in any patients.
Skip lesions in long bone chondrosarcoma are rare. All skip lesions in this study were in close proximity to the primary tumor and the same grade as the main lesion. Our results suggest that advanced imaging of the whole bone may be of low utility for evaluating the presence of skip lesions. The clinical significance of skip lesions in chondrosarcoma remains unclear, however, their presence did not impact the treatment plan in this series.
骨肉瘤中的跳跃性病变是一种描述较少的实体。骨肉瘤和尤因肉瘤中关于跳跃性病变的报告表明,鉴于其与更差预后相关,应进行全骨磁共振成像(MRI)以评估是否存在其他肿瘤病灶。然而,支持软骨肉瘤全骨成像的证据有限。
1995年至2022年期间,我们机构对129例长骨软骨肉瘤患者进行了评估。病变最常见于64例患者的股骨和54例患者的肱骨。回顾了所有影像学研究和病理报告,以确定跳跃性病变的存在,跳跃性病变定义为经组织学证实的软骨肉瘤区域,在病理上与原发病变被正常骨分隔开。
107例患者在初始分期时进行了全骨成像,其中三分之二的患者接受了MRI、计算机断层扫描(CT)或骨扫描。5例患者(3.9%)在与原发肿瘤相同的骨中发现有跳跃性病变。没有跨关节跳跃性病变。在3例低级别软骨肉瘤患者(4.6%)和2例高级别软骨肉瘤患者(3.2%)中检测到跳跃性病变。所有病变均在原发肿瘤2厘米范围内。所有病变在原发部位的MRI和CT上均可见,1例在平片上可见。跳跃性病变的存在未改变任何患者的手术治疗方式。
长骨软骨肉瘤中的跳跃性病变很少见。本研究中的所有跳跃性病变均紧邻原发肿瘤且与主要病变级别相同。我们的结果表明,全骨的高级成像对于评估跳跃性病变的存在可能效用较低。软骨肉瘤中跳跃性病变的临床意义仍不清楚,然而,它们的存在并未影响本系列中的治疗计划。